SCHEMBL4691645

SCHEMBL4691645

O=C(Cl)Cc1ccc(F)c(Br)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 3/20 0.41
FAAH O00519 1/20 0.40
PIK3CA P42336 1/20 0.39
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
PARP1 P09874 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HDAC1 Q13547 3/20 0.36
HDAC6 Q9UBN7 3/20 0.36
SLC9A1 P19634 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77380 0.83 KDM4E (0.50) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL2173469 0.82 MAPK8 (0.44) PIK3CAMAOAMAOBALDH1A1HDAC1
SCHEMBL17606043 0.82 PARP1 (0.41) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL29468719 0.81 CA2 (0.47) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL19641588 0.81 CA2 (0.47) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL21090110 0.79 PIK3CA (0.58) KDM4EPIK3CAALDH1A1TSHRIDO1
SCHEMBL12672485 0.78 MMP13 (0.47) PIK3CAALDH1A1HDAC1HDAC8
SCHEMBL31048328 0.77 FAAH (0.43) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL137265 0.77 ALDH1A1 (0.51) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL1150357 0.76 MAPT (0.44) PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024178304-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-08-29 WO disclosed
CN-107954999-B Oxadiazole ring-containing compound, preparation method, intermediate, composition and application 上海医药集团股份有限公司 2023-01-24 CN disclosed
EP-1603901-B1 TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS MERCK SHARP & DOHME (GB) 2008-10-15 EP disclosed
US-7393858-B2 Tetrahydropyran compounds as tachykinin antagonists MERCK SHARP & DOHME LTD. (GB) 2008-07-01 US disclosed
US-20060172999-A1 Tetrahydropyran compounds as tachykinin antagonists MERCK SHARP & DOHME LTD. (GB) 2006-08-03 US disclosed
EP-1603901-A1 TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2005-12-14 EP disclosed
WO-2004078750-A1 TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060172999-A1 Tetrahydropyran compounds as tachykinin antagonists NPSR1, NPY1R, OPRL1 CYP1A2 2965/4885CYP2D6 1274/4885CYP2C9 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.